CBIH (Cannabis Bioscience International Holdings) EBIT: $-0.32 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Bioscience International Holdings EBIT?

Cannabis Bioscience International Holdings CBIH +33.33% EBIT is $-0.32 Mil as of Feb. 2026. The stock has 4 warning signs investors should review.

Cannabis Bioscience International Holdings's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was $-0.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cannabis Bioscience International Holdings's annualized ROC % for the quarter that ended in Feb. 2026 was -237.70%. Cannabis Bioscience International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cannabis Bioscience International Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -11.83%.

Cannabis Bioscience International Holdings  (OTCPK:CBIH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cannabis Bioscience International Holdings's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-0.372 * ( 1 - 0% )/( (0.157 + 0.156)/ 2 )
=-0.372/0.1565
=-237.70 %

where

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.022 - 0.979 - ( 0 - max(0, 1.136 - 0.022+0))
=0.157

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.002 - 1.063 - ( 0 - max(0, 1.219 - 0.002+0))
=0.156

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cannabis Bioscience International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.372/( ( (0 + max(-0.957, 0)) + (0 + max(-1.06, 0)) )/ 2 )
=-0.372/( ( 0 + 0 )/ 2 )
=-0.372/0
= %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.022 + 0 + 0) - (0.979 + 0 + 0)
=-0.957

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.001) - (1.063 + 0 + -0.00099999999999989)
=-1.06

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cannabis Bioscience International Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-0.323/2.731
=-11.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Bioscience International Holdings EBIT Related Terms

Cannabis Bioscience International Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Cannabis Bioscience International Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Bioscience International Holdings EBIT Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11 May23 May24 May25
EBIT
Get a 7-Day Free Trial -12.42 14.57 -0.94 -0.49 -0.37

Cannabis Bioscience International Holdings Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.09 -0.05 -0.10 -0.09

CBIH vs SXTC, UPC, NPHC: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's EV-to-EBIT falls into.


Cannabis Bioscience International Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.32 Mil mean?
Cannabis Bioscience International Holdings (CBIH) has a EBIT of $-0.32 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cannabis Bioscience International Holdings.
Is Cannabis Bioscience International Holdings' EBIT too high?
Cannabis Bioscience International Holdings' current EBIT is $-0.32 Mil.
How does Cannabis Bioscience International Holdings' EBIT compare to SXTC and UPC?
Cannabis Bioscience International Holdings' EBIT of $-0.32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cannabis Bioscience International Holdings. Cannabis Bioscience International Holdings's current EBIT is $-0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current EBIT of $-0.32 Mil. The current EBIT is $-0.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current EBIT is $-0.32 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Bioscience International Holdings Business Description

Address 6201 Bonhomme Road, Suite 435N, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.